Anti-CEA tagged iron nanoparticles for targeting triple-negative breast cancer

• Published in: Biomedical materials (Bristol) 2021-05, Vol.16 (3), p.35017
• Main Authors: Correa, Thais S, Bocca, Anamélia L, Figueiredo, Florêncio, Lima, Emilia C O, Almeida Santos, Maria De Fatima M, Lacava, Zulmira G M, Campos-da-Paz, Mariana
• Format: Article
• Language: English
• Subjects: Animals; Carcinoembryonic Antigen - therapeutic use; Cell Line, Tumor; Humans; Iron; Mice; Nanoparticles - chemistry; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - metabolism; Triple Negative Breast Neoplasms - pathology
• ISSN: 1748-6041; 1748-605X
• DOI: 10.1088/1748-605X/abe359

Systemic therapy is generally required for breast cancer. However, treatment toxicity and side effects are a concern, especially for triple-negative breast cancer (TNBC), a subtype that usually develops resistance to chemotherapy. To overcome this issue, new nanoformulations capable of targeting cancer cells have been developed and alternative biomarkers have been explored as target molecules for TNBC management. In this study, we performed an assay in a murine orthotopic TNBC model to evaluate the targeting ability of anti-carcinoembryonic antigen (anti-CEA) loaded nanoparticles (labelled MFCEA), which had been previously synthetized by our research group. 4T1 cells were injected in the mammary gland of balb-c mice, and tumors were evaluated for CEA expression by immunohistochemistry. Tumor-bearing mice received targeted (MFCEA) and non-targeted (MF) nanoparticles intraperitoneally. Tumors were removed 1, 4, 15 and 24 h after treatment, and Prussian blue iron staining was performed. Our results showed, as far as we know for the first time, that 4T1 induced tumors are CEA positive, and this opens up new prospects for treating TNBC. Furthermore, MFCEA nanoparticles were able to target malignant tissue and were retained in the tumor for longer than MF nanoparticles. The retention property of MFCEA, together with the absence of toxicity observed in the MTT assay, make these nanoparticles a promising device for management of CEA positive tumors and perhaps for TNBC. Nevertheless, further studies must be carried out to improve their performance and ensure safety for clinical studies.